ESTHETIK MED: what changed
ESTHETIK MED
Largest movements
- Tangible fixed assets +€6,113
up €6,113 (+143%), from €4,261 to €10,374
of which Plant, machinery and equipment: +€6,583
- Receivables within one year +€770
new in 2025: €770
- Deferred charges and accrued income +€564
up €564 (+28.5%), from €1,980 to €2,544
- Financial fixed assets -€500
no longer reported in 2025 (was €500)
- Other debts +€10,166
up €10,166 (+6.4%), from €158,240 to €168,406
- Profit (loss) carried forward -€7,472
down €7,472 (-4.7%), from -€159,475 to -€166,947
- Trade debts +€4,920
up €4,920 (+424%), from €1,160 to €6,080
- Accrued charges and deferred income -€750
no longer reported in 2025 (was €750)
- Gross operating margin +€12,354
up €12,354 (+74.5%), from -€16,591 to -€4,237
- Other operating charges -€1,669
down €1,669 (-86.6%), from €1,928 to €259
- Depreciation +€441
up €441 (+17.9%), from €2,468 to €2,910
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €6,875 | €13,739 | +€6,864 | +99.8% |
| Fixed assets | 21/28 | €4,761 | €10,374 | +€5,613 | +118% |
| Tangible fixed assets | 22/27 | €4,261 | €10,374 | +€6,113 | +143% |
| Plant, machinery and equipment | 23 | €3,791 | €10,374 | +€6,583 | +174% |
| Furniture and vehicles | 24 | €470 | - | -€470 | |
| Financial fixed assets | 28 | €500 | - | -€500 | |
| Current assets | 29/58 | €2,114 | €3,365 | +€1,251 | +59.2% |
| Amounts receivable within one year | 40/41 | - | €770 | +€770 | |
| Trade receivables | 40 | - | €770 | +€770 | |
| Cash at bank and in hand | 54/58 | €134 | €51 | -€83 | -61.7% |
| Deferred charges and accrued income | 490/1 | €1,980 | €2,544 | +€564 | +28.5% |
| Total equity and liabilities | 10/49 | €6,875 | €13,739 | +€6,864 | +99.8% |
| Equity | 10/15 | -€153,275 | -€160,747 | -€7,472 | -4.9% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€159,475 | -€166,947 | -€7,472 | -4.7% |
| Amounts payable | 17/49 | €160,150 | €174,486 | +€14,336 | +9.0% |
| Amounts payable within one year | 42/48 | €159,400 | €174,486 | +€15,086 | +9.5% |
| Trade debts | 44 | €1,160 | €6,080 | +€4,920 | +424% |
| Suppliers | 440/4 | €1,160 | €6,080 | +€4,920 | +424% |
| Other amounts payable | 47/48 | €158,240 | €168,406 | +€10,166 | +6.4% |
| Accrued charges and deferred income | 492/3 | €750 | - | -€750 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,468 | €2,910 | +€441 | +17.9% |
| Other operating charges | 640/8 | €1,928 | €259 | -€1,669 | -86.6% |
| Gross operating margin | 9900 | -€16,591 | -€4,237 | +€12,354 | +74.5% |
| Operating profit (loss) | 9901 | -€20,987 | -€7,406 | +€13,582 | +64.7% |
| Financial income | 75/76B | €24 | - | -€24 | |
| Recurring financial income | 75 | €24 | - | -€24 | |
| Financial charges | 65/66B | €48 | €66 | +€18 | +36.7% |
| Recurring financial charges | 65 | €48 | €66 | +€18 | +36.7% |
| Profit (loss) for the period before taxes | 9903 | -€21,012 | -€7,472 | +€13,540 | +64.4% |
| Profit (loss) for the period | 9904 | -€21,012 | -€7,472 | +€13,540 | +64.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€21,012 | -€7,472 | +€13,540 | +64.4% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 4 November 2026 via checked.be.